Loading clinical trials...
Loading clinical trials...
The goal of this study is to identify reliable markers of LRRK2 activity in human CSF.
Specific aims of this project are: Primary Objectives: To evaluate each assay performance for its ability to detect LRRK2, its activity and/or the detection and activity of the pathways it impacts using a variety of different approaches (quantitative western blot, immunoassays and LC-MS). Assay performance will be assessed and those demonstrating high sensitivity and consistency will be considered for further development. Secondary Objectives: To assess the ability of the assay or a combination of assays to differentiate pathogenic LRRK2 variant manifesting and non-manifesting carriers, idiopathic PD and healthy non-carriers.
Age
30 - No limit years
Sex
ALL
Healthy Volunteers
Yes
Northwestern University
Chicago, Illinois, United States
The Trustees of Columbia University
New York, New York, United States
Oregon Health Sciences Univeristy
Portland, Oregon, United States
The Trustees of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
Start Date
May 6, 2021
Primary Completion Date
July 1, 2023
Completion Date
July 1, 2023
Last Updated
October 16, 2023
140
ACTUAL participants
Lumbar Puncture
PROCEDURE
Lead Sponsor
Michael J. Fox Foundation for Parkinson's Research
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06113640